Study: Newly Identified Genes Linked with Higher Risk for Triple-Negative Breast Cancer
We've known that mutations in the BRCA1 and BRCA2 genes are linked with an increased risk for breast cancer. Now we know about 5 other genes associated with a high risk for triple negative breast cancer (TNBC) thanks to a study by former American Cancer Society grant recipient, Fergus J. Couch, PhD. Knowing these genes can help doctors improve the screening process for women who have a personal or family history of breast or ovarian cancer. Identifying them also allows new treatments for TNBC to be tested.
Study: Obesity Linked to Colorectal Cancer in Young Women
New research shows obesity may be contributing to increasing rates of colorectal cancer among younger Americans.
Leukemia Survivor Opens Up About His Cancer
Leukemia survivor Lloyd Sutton says the only time he really felt shaky was the night he spent in the emergency room in May 2015.
Get Moving to Help Reduce Your Risk of Breast Cancer
Engaging in regular exercise is good for you for many reasons, and one of them is to lower your risk of getting breast cancer.
A Pioneer in Developing Drugs for People with T-Cell Lymphoma
Owen A. O'Connor, MD, PhD, was awarded the prestigious American Cancer Society Clinical Research Professor grant in July 2018. He was selected because of his expertise and ongoing work to develop drugs to improve treatments for people with Hodgkin and non-Hodgkin lymphomas. He's a professor and researcher at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center in New York, New York.
Five Ways to Reduce Your Breast Cancer Risk
Although there is no sure way to prevent breast cancer, there are several things you can do that may lower your likelihood of getting it.
If You’re Called Back After a Mammogram
Women getting their routine mammogram will often receive a letter within 30 days saying the results were normal. However, getting called back after a screening mammogram is fairly common and can be scary.
FDA Approves Libtayo (Cemiplimab) for a Type of Skin Cancer
The US Food and Drug Administration (FDA) has approved Libtayo (cemiplimab) to treat people with advanced squamous cell carcinoma of the skin.